Accordingly, a study reported that elevated ULK1, a modulator of autophagy, along with mitochondrion-associated autophagy inhibitor (LRPPRC), could be used as a biochemical marker to assess cancer progression and patient OS in patients with metastatic prostate cancer [53]. The gene discussed is ULK1; the disease is metastatic prostate carcinoma.